Abstract

Objective- NRP1(neuropilin-1) acts as a coreceptor for VEGF (vascular endothelial growth factor) with an essential role in angiogenesis. Recent findings suggest that posttranslational proteolytic cleavage of VEGF receptors may be an important mechanism for regulating angiogenesis, but the role of NRP1 proteolysis and the NRP1 species generated by cleavage in endothelial cells is not known. Here, we characterize NRP1 proteolytic cleavage in endothelial cells, determine the mechanism, and investigate the role of NRP1 cleavage in regulation of endothelial cell function. Approach and Results- NRP1 species comprising the carboxy (C)-terminal and transmembrane NRP1 domains but lacking the ligand-binding A and B regions are constitutively expressed in endothelial cells. Generation of these C-terminal domain NRP1 proteins is upregulated by phorbol ester and Ca2+ ionophore, and reduced by pharmacological inhibition of metalloproteinases, by small interfering RNA-mediated knockdown of 2 members of ADAM (a disintegrin and metalloproteinase) family, ADAMs 9 and 10, and by a specific ADAM10 inhibitor. Furthermore, VEGF upregulates expression of these NRP1 species in an ADAM9/10-dependent manner. Transduction of endothelial cells with adenoviral constructs expressing NRP1 C-terminal domain fragments inhibited VEGF-induced phosphorylation of VEGFR2 (VEGF receptor tyrosine kinase)/KDR (kinase domain insert receptor) and decreased VEGF-stimulated endothelial cell motility and angiogenesis in coculture and aortic ring sprouting assays. Conclusions- These findings identify novel NRP1 species in endothelial cells and demonstrate that regulation of NRP1 proteolysis via ADAMs 9 and 10 is a new regulatory pathway able to modulate VEGF angiogenic signaling.

Highlights

  • NRP1 acts as a coreceptor for VEGF-A, forming heterocomplexes with the VEGFR2 (VEGF receptor tyrosine kinase), which mediate optimal VEGF signaling and endothelial cell migration essential for angiogenesis.[3,4,5]

  • Transduction of Human umbilical vein endothelial cells (HUVECs) with an adenoviral construct encoding full-length wild-type NRP1 resulted in increased expression of both a major 130 kDa band corresponding to full-length NRP1, and of 2 lower molecular weight bands, of 10, and 15 kDa, very similar in size to endogenous bands detected in HUVECs that were recognized by cytoplasmic domain antibody, but not by antibody directed to the extracellular NRP1 domain (Figure 1C)

  • Cytoplasmic Domain NRP1 Fragments Are Generated via Proteolytic Cleavage by ADAMs 9 and 10 To test the possibility that expression of small C-terminal NRP1 fragments could result from proteasomal or lysosomal degradative pathways, we examined whether inhibitors of endocytotic trafficking and lysosomal or proteasomal degradation had any effect on expression of NRP1 cytoplasmic domain species.[17]

Read more

Summary

Methods

The data that support the findings of this study are available from the corresponding author on reasonable request. Human umbilical vein endothelial cells (HUVECs) were purchased from TCS CellWorks (Bucks, United Kingdom) and cultured in endothelial basal medium (Cambrex BioScience Ltd, Nottingham, United Kingdom) supplemented with gentamicin-ampicillin, epidermal growth factor, bovine brain extract (Singlequots; Cambrex), and 10% fetal bovine serum (Life Technologies, Paisley, United Kingdom). Phospho-VEGFR2 (Y1175, number 2478) and Notch intracellular cleavage domain (number 4147) antibodies were from Cell Signaling Technology Inc (Danvers, MA). Antibody to ADAM10 was from Sigma Aldrich Predesigned small interfering RNAs (siRNAs) targeted against ADAMs 9, 10, 17 (Table) or scrambled control were purchased from GE Healthcare (Little Chalfont, United Kingdom) and used for transfection as previously described.[7] PMA, GI254023X, marimastat, chloroquine, and lactacystin were purchased from Sigma Aldrich (Dorset, United Kingdom); Ionomycin was purchased from Merck Millipore (Herts, United Kingdom)

Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call